Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Webcast ImageWebcast - Replay
RNAi Roundtable: ALN-PCSsc for the Treatment of Hypercholesterolemia
08/14/14 at 4:00 p.m. ET
Webcast ImageWebcast - Replay
ORBACTIV™ FDA Approval
08/07/14 at 8:00 a.m. ET
Webcast ImageWebcast - Replay
Q2 2014 The Medicines Company Earnings Conference Call
07/23/14 at 8:30 a.m. ET
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$26.34
Change (%) Stock is Up 0.16 (0.61%)
Volume446,981
Data as of 08/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
08/07/14The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast “ALN-PCSsc for the Treatment of Hypercholesterolemia”
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 7, 2014-- The Medicines Company (NASDAQ:MDCO) today announced that in collaboration with Alnylam Pharmaceuticals (NASDAQ:ALNY) it will be hosting the “ALN-PCSsc for the treatment of Hypercholesterolemia” RNAi Roundtable webcast on August 14, 2014. Event details are below. RNAi Roundtable webcast: “ALN-PCSsc for the treatment of Hypercholesterolemia” Thursday, August 14 @ 4:00 p.m. - 5:00 p.m. ET ... 
Printer Friendly Version
08/06/14FDA Approves The Medicines Company's ORBACTIV™ (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections
First and Only Single Dose Antibiotic for the Treatment of Skin Infections Caused by Susceptible Designated Gram-positive Bacteria ORBACTIV™U.S. Launch Expected in 2H/2014 PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 6, 2014-- The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration (FDA) has approved ORBACTIV™ (oritavancin) for injection for the treatment of adults with acute bacterial skin and skin st... 
Printer Friendly Version
08/04/14The Medicines Company to Host Infectious Disease Care Investor and Analyst Meeting on September 24, 2014
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 4, 2014-- The Medicines Company (NASDAQ:MDCO) has scheduled an Infectious Disease Care Investor and Analyst meeting for Wednesday, September 24, 2014 from 8:30 am to 12:00 noon. The event will be held at the Company’s Global Center 1 at 8 Sylvan Way in Parsippany, NJ. The meeting is being hosted to highlight The Medicines Company’s emerging core business in Infectious Disease Care. Investors and Anal... 
Printer Friendly Version
07/23/14The Medicines Company Reports Second Quarter and First Half 2014 Results
Second Quarter Net Revenues Rise 6%, First Half Net Revenues Rise 10%; Company continues year-over-year growth in revenue Company Reports Progress of Four Regulatory Applications for US and Europe R&D Portfolio Progress PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 23, 2014-- The Medicines Company (NASDAQ:MDCO), a global company focused on saving lives, alleviating suffering, and contributing to the economics of healthcare by ... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.